Gallego Continues to Push for Answers on Trump’s Pharmaceutical Deals

WASHINGTON– In response to President Trump’srecent announcementthat nine drugmakers agreed to direct-to-consumer pricing through the TrumpRx drug purchasing platform, and the implementation of “Most Favored Nation” (MFN) pricing in Medicaid,Senator Ruben Gallego (D-AZ)called on the drug manufacturers to clarify the agreement and provide the public with details on the arrangement.
“It raises concern that to date, the public has been provided with only limited details, despite the significance of this arrangement for millions of patients, and that in return for this arrangement [these companies] will get a three-year exemption from Section 232 tariffs,”Senator Gallego wrote in the letters to the drug manufacturers.
In the letters, Senator Gallego asks the drug manufacturers the following questions:
As currently described, this model would require patients to bypass their insurance and pay cash for medications — often at high out-of-pocket costs. Given that many insured patients already have lower copays or coinsurance than the proposed TrumpRx discounts, it is unclear how this platform would provide meaningful relief. In fact, it may increase costs for patients,”Senator Gallego concludes the letters.
Senator Gallego sent the letters to the nine companies included in President Trump’s most recent announcement. These companies include:
These letters build on Senator Gallego’s efforts to get more information on how these deals will impact Americans. He recentlysent lettersto Eli Lilly and Novo Nordisk, and alsocalled on Pfizerand AstraZeneca to clarify similar questions about the companies’ pricing metrics that will be used in the MFN formula and what the full scope of drugs subject to MFN pricing in Medicaid will be.